We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 05, 2021

Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After ACS or PCI

Circulation

 

Additional Info

Circulation
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights From The AUGUSTUS Trial
Circulation 2021 Jan 19;[EPub Ahead of Print], Z Hijazi, JH Alexander, Z Li, DM Wojdyla, R Mehran, CB Granger, A Parkhomenko, MC Bahit, S Windecker, R Aronson, O Berwanger, S Halvorsen, S de Waha-Thiele, P Sinnaeve, H Darius, RF Storey, RD Lopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading